Triple Therapy Demonstrates 100% Cure Rate in Mouse Model of Melanoma
Source: Technology Networks, May 2022
A combination of two existing skin cancer drugs and a third experimental drug could lead to a new strategy for treating patients who do not respond to existing therapies, a new study in mice suggests.
The researchers found that the triple therapy cured 100 per cent of the mice in the study. They hope these findings will feed into future clinical trials looking to improve advanced melanoma skin cancer treatment.
Scientists studied mice with colour-changing fluorescent immune cells to look at how the existing melanoma drugs work. This is one of the first times this innovative technique has been applied to studying cancer immunology. The method allowed them to spot a target for an additional drug which, when combined with the two existing drugs, boosted the antitumour effect in the mice.